WOLF GREENFIELD WEBCAST: CRISPR/Cas-9 and the IP Landscape for a Revolutionary New Technology
CRISPR/Cas-9 is a new genomic editing system that has the potential to revolutionize basic biomedical research and, possibly, the treatment of genetic disease. The CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) system utilizes guide RNA as a gene-homing mechanism and a Cas-9 nuclease to cut targeted DNA. As such, it drastically reduces the time-to-results and design complexity associated with existing genomic editing tools.
Given CRISPR’s simplicity and widespread applicability in biomedical research, scientists and university technology licensing officers are understandably asking about intellectual property rights and access to this technology, both today and looking forward.
This seminar will address the following questions:
What is the CRISPR/Cas-9 system and how does it work as a genome editing tool?
What are CRISPR’s advantages over existing genomic editing systems?
What does the IP landscape look like for this technology and what might it look like in the future?
What are the possible impacts of intellectual property on scientists’ ability to carry out research using CRISPR/Cas-9?
What are the possible impacts on technology officers’ ability to license technology that involves CRISPR/Cas9?
Patricia Granahan, Shareholder, Biotechnology Group, Wolf Greenfield
Chelsea Loughran, Associate, Litigation Group, Wolf Greenfield